Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells

Although farnesyltransferase inhibitors have shown promising activity in relapsed lymphoma and sporadic activity in acute myelogenous leukemia, their mechanism of cytotoxicity is incompletely understood, making development of predictive biomarkers difficult. In the present study, we examined the act...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ding, Husheng, McDonald, Jennifer S., Yun, Seongseok, Schneider, Paula A., Peterson, Kevin L., Flatten, Karen S., Loegering, David A., Oberg, Ann L., Riska, Shaun M., Huang, Shengbing, Sinicrope, Frank A., Adjei, Alex A., Karp, Judith E., Meng, X. Wei, Kaufmann, Scott H.
Formato: Artigo
Lenguaje:Inglês
Publicado: Ferrata Storti Foundation 2014
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007940/
https://ncbi.nlm.nih.gov/pubmed/23996484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.087734
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares